Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IVS-3001 |
Synonyms | |
Therapy Description |
IVS-3001 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting HLA-G, which potentially enhance antitumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IVS-3001 | IVS 3001|IVS3001 | IVS-3001 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting HLA-G, which potentially enhance antitumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05672459 | Phase Ib/II | IVS-3001 Cyclophosphamide + Fludarabine | A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors | Recruiting | USA | 0 |